Business
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor and medical conferences, including presentations featuring VIZZ at Academy 2025 presented by the American Academy of Optometry. Citi’s 2025 BioPharma Back to School ConferenceDate: September 2-3, 2025Location: Boston, MAFormat: Fireside chat at 9:45am EDT (live audio webcast) and 1x1 investor meetings Cantor Global Healthcare ConferenceDate: September 4, 2025Location: New York City, NYFormat: Fireside chat at 1:35pm EDT (live audio webcast) and 1x1 investor meetings H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 9, 2025Location: New York City, NYFormat: Company presentation at 11:00am EDT (live audio webcast) and 1x1 investor meetings Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: September 10, 2025Location: New York City, NYFormat: Fireside chat at 10:00am EDT (live audio webcast) and 1x1 investor meetings Live audio webcasts will also be available on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcasts will be available on the Company’s website for 12 months following the event. Academy 2025 Boston presented by the American Academy of Optometry Title:Efficacy and Performance Measures for Presbyopia Treatment with Aceclidine 1.44% Ophthalmic SolutionFormat:Oral podium presentationPresenter:Jason Miller, ODDay/Time:October 8, 2025; 9:30am EDTSession:P-01 Clinical Optics and Biometry (Room 257 A/B); 8:15am-9:45am EDTLocation:Thomas Michael M. Convention and Exhibition Center; Boston, MA Title:Clinical Confirmation of Optimal Pupil Size for Miotic Treatment of PresbyopiaFormat:Poster presentationPresenter:Milton Hom, ODDay/Time:October 9, 2025; 4:30pm-6:30pm EDTSession:POS-01 Scientific Program Poster Session (Exhibit Hall)Location:Thomas Michael M. Convention and Exhibition Center; Boston, MA About PresbyopiaPresbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people ove...